Nitib (Ibrutinib) 140 mg
Nitib is a breakthrough targeted therapy for B-cell malignancies. Active ingredient: Ibrutinib (140 mg).
Manufacturer: Hetero Healthcare (India). Generic equivalent of Imbruvica.
Mechanism:
Nitib acts as a Bruton's Tyrosine Kinase (BTK) inhibitor. By permanently bonding to the BTK protein, it shuts down the survival signals within malignant B-cells, causing them to die or stop multiplying.
✅ Key Benefit: An oral, chemotherapy-free option that offers long-term disease control.
Indicated for the treatment of:
- Chronic Lymphocytic Leukemia (CLL) / Small Lymphocytic Lymphoma (SLL).
- Mantle Cell Lymphoma (MCL): For patients who have received at least one prior therapy.
- Waldenström's Macroglobulinemia (WM).
Strength: 140 mg per capsule.
Daily Regimen (Once Daily):
- CLL & Waldenström's: 420 mg = Take 3 capsules daily.
- Mantle Cell Lymphoma: 560 mg = Take 4 capsules daily.
⚠️ Instructions: Swallow whole with water at the same time each day. Avoid Grapefruit and Seville oranges completely.
🚫 SURGERY WARNING (Bleeding Risk):
Ibrutinib increases the risk of bleeding. Therapy should be interrupted for 3 to 7 days prior to and after any surgery (including dental work), depending on the surgery type and bleeding risk.
Other Contraindications:
- Severe hepatic impairment.
- Pregnancy and breastfeeding.
- Concomitant use of Warfarin (increases hemorrhage risk).
Monitor for the following:
- Bleeding/Bruising: Very common. Report severe bleeding immediately.
- Diarrhea: Stay hydrated.
- Cardiac Arrhythmias: Atrial fibrillation (irregular heartbeat) may occur.
- Musculoskeletal pain and fatigue.
Similar products
What Customers Say
No reviews yet
Your review can be the first!